Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

We are currently facing an issue in receiving the NSE feed. Hence the stock prices are not updated. We are working on fixing this at the earliest. We regret the inconvenience caused.

Indian markets continue to slide
Tue, 14 Jan 01:30 pm

Indian stock markets continued to slide further and slipped into negative territory during the post noon trading session. Almost all sectoral indices are trading in the red. Realty and metal indices are the biggest losers.

The BSE Sensex is trading down 80 points and the NSE-Nifty is trading down 27 points. The BSE Mid Cap index is trading down 0.3% and BSE Small Cap index is trading lower by 0.1%. The rupee is trading at 61.52 to the US dollar.

Indian private banking stocks are trading mixed. Kotak Mahindra and Axis Bank are the major losers, while Yes Bank is trading firm. As per a leading business daily, Indian government plans to sell its 12% holding in Axis Bank, India's third largest private bank. Government has 20.72% stake in the bank through The Special Undertaking of Unit Trust of India (SUUTI). The stake sale in the bank would entail exchequer about Rs 60 bn in value. Earlier, the government had increased the FII limit in the Indian companies to 62% from 49%. FII holding in Axis Bank is currently about 45%. Further, the government has stake through SUUTI in three other private companies and it has plans to sell the same in all the companies. However, SUUTI stake sale plan in ITC and L&T is put on hold for the time being. The stock of Axis Bank is trading down by 1% today.

Pharma stocks are also trading mixed. Strides Arcolab and Indoco Remedies are trading in the green, while Ranbaxy is the major loser. As per a leading financial daily, Ranbaxy said the US FDA has filed certain observations about its Toansa pharmaceutical ingredients plant in Punjab. This is the fourth such Ranbaxy's plant where US FDA has raised its concern. The Toansa plant is crucial for the pharma major as about 70% of APIs used in its formulations are expected to be manufactured in the plant. Off late, the company has not been able to fetch approvals of products on time especially for those where its holds exclusivity. This led to delays in the launch of key products. The new issue would further increase its risk of delay in resolution of import alerts and launch of products. Notably, getting timely approvals and resolving USFDA issues will be the key in bolstering overall growth. Ranbaxy has also been witnessing margin pressures on account of resolving its plant issues.The stock was down 2.6% at the time of writing.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian markets continue to slide". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.